Stereotactic body radiotherapy for unresectable cholangiocarcinoma

Kopek, Neil; Holt, Marianne Ingerslev; Hansen, Aviaja Anna; Høyer, Morten

doi:10.1016/j.radonc.2009.11.004

Cited by 152 publications

(111 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prospective trials with dose escalation demonstrate this dose effect relation. 10,17-22, 43 Andratschke 10 treated 71 patients with 91 metastasis (mets). Treatment consisted of 3-5 fractions with 5-12.5 Gy/fraction prescribed to the surrounding 60-95% isodose.…”

Section: Dosementioning

confidence: 99%

“…20 A few gastric acute toxicities have been reported. Kopek 43 describes an acute gastric toxicity with two grade 3 nausea for 44 patients. Herfarth et al 3 also describes nausea and anorexia for 11 patients on the 37 accrued.…”

Section: Stomach Duodenal and Bowel Toxicitiesmentioning

confidence: 99%

“…The predictive dosimetric parameters were a V15 < 9.1 cc, a V20 < 3.3 cc and a Dmax > 23 Gy. Applying the same prescription to 27 cholangiocarcinoma, Kopek et al 43 observed 22% of gastric or duodenal ulcerations after a median delay of 6.7 months requiring hospitalization and blood transfusion, a duodenal stenosis for 4 patients (11%), two of them requiring dilatation. The probability of grade higher or equal to 2 ulceration was correlated to the maximal dose delivered to 1 cc of the duodenum.…”

Section: Stomach Duodenal and Bowel Toxicitiesmentioning

confidence: 99%

See 2 more Smart Citations

Dose to organ at risk and dose prescription in liver SBRT

Rives

Izar

Parent

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.

show abstract

Section: Dosementioning

confidence: 99%

Section: Stomach Duodenal and Bowel Toxicitiesmentioning

confidence: 99%

Section: Stomach Duodenal and Bowel Toxicitiesmentioning

confidence: 99%

See 1 more Smart Citation

Dose to organ at risk and dose prescription in liver SBRT

Rives

Izar

Parent

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Treatment of hilar CC was reported by Kopek et al and included 27 patients who were treated with SBRT to a higher total dose of 45 Gy in 3 fractions (41). Seventy-eight percent of these patients were deemed inoperable due to , all patients were CTP-B or CTP-C. SBRT, stereotactic body radiation therapy; GTV, gross tumor volume; BED 10 , biologic effective dose using an alpha-beta ratio of 10 Gy; NR, not reported; CTP, Child-Turcotte-Pugh; NS, non-significant; OS, overall survival.…”

Section: Sbrt For CCmentioning

confidence: 99%

Radiation therapy for hepatobiliary malignancies

Lischalk

Repka

Unger

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

“…In unresectable CCA, conventional treatment modalities, including chemotherapy and radiotherapy, may prolong patient survival; however, the results thus far are discouraging (17)(18)(19)). An alternative radiation modality, stereotactic body radiation therapy, has also failed to improve the survival of unresectable CCA patients (20). Tumor -related hepatic failure due to disease recurrence is the leading cause of patient mortality, exceeding that of other causes combined, such as distant metastasis, infection or angiocholitis (21).…”

Section: Introductionmentioning

confidence: 99%

Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy

Nantajit

Trirussapanich

Rojwatkarnjana

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Cholangiocarcinoma (CCA) or bile duct cancer is a rare cancer type in developed countries, while its prevalence is increased in southeast Asia, affecting ~33.4 men and ~12.3 women per 100,000 individuals. CCA is one of the most lethal types of cancer. Neo-adjuvant and adjuvant therapies have been shown to have limited efficacy in improving the overall prognosis of patients. Radiotherapy has been reported to prolong the survival times of patients with certain characteristics. The present study retrospectively evaluated the medical records and follow-up data from 27 CCA patients who received radiotherapy at Chulabhorn Hospital (Bangkok, Thailand) between 2008 and 2014. A total of 14 patients underwent surgery followed by adjuvant chemoradiotherapy. Of the 27 CCA patients, 14 had intrahepatic CCA, 2 had extrahepatic CCA and 11 had hilar CCA. The 2-year survival rate was 40.7%. Tumor resectability, clinical symptoms and the Eastern Cooperative Oncology Group performance status score were found to be indicative of patient prognosis. In addition, the planning target volume and biologically effective radiotherapy dose were of prognostic value; however, initial treatment response was ambiguous in predicting survival time. The findings of the present study suggested that the currently used radiotherapy protocols for CCA may require modification to improve their efficacy.

show abstract

Stereotactic body radiotherapy for unresectable cholangiocarcinoma

Cited by 152 publications

References 32 publications

Dose to organ at risk and dose prescription in liver SBRT

Dose to organ at risk and dose prescription in liver SBRT

Radiation therapy for hepatobiliary malignancies

Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy

Contact Info

Product

Resources

About